



B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL)

Guest Editors:

Dr. Victor Peperzak

Principal Investigator Division Laboratories, Pharmacy and Biomedical Genetics, Center for Translational Immunology, section Tumor Immunology | University Medical Center Utrecht | Room number H2.126 | Internal mail no F03.821 | Heidelberglaan 100, 3508 AB UTRECHT, The Netherlands.

Dr. Marta Cuenca Lopera

Division Laboratories, Pharmacy and Biomedical Genetics, Center for Translational Immunology, section Tumor Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands

Deadline for manuscript submissions:
closed (31 October 2020)

Message from the Guest Editors

B cell malignancies comprise a heterogeneous group of cancers, including B cell lymphomas, B cell leukemias and plasma cell dyscrasias, and combined constitute the fifth most common cancer in adults. The majority of B cell malignancies originate from germinal center B cells where the enzyme activation-induced deaminase (AID), essential for creating antibody diversification, can introduce mutations of proto-oncogenes and chromosomal translocations that result in cancer development.

Over the last decades, basic research on the pathogenesis of B cell malignancies has provided significant insights about the mechanisms that underlie disease progression, malignant cell survival and drug resistance, often leading to successful shifts in treatment paradigms. However, despite these advances, many B cell malignancies are still considered incurable.

This Special Issue will highlight the development of novel treatment options, including targeted therapies, combination treatment and immunotherapeutic approaches that cover basic, translational and (pre)clinical aspects aiming to improve treatment of B cell malignancies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)